Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma

This study has been withdrawn prior to enrollment.
(Withdrawn prior to initiation.)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
AIDS Malignancy Consortium Identifier:
First received: September 13, 2001
Last updated: January 22, 2013
Last verified: January 2013

September 13, 2001
January 22, 2013
August 2001
March 2003   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00024128 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma
Delayed Donor Leukocyte Infusions in Patients Receiving Allogeneic PBSC Following Conditioning With Non-myeloablative Regimen for AIDS-Related Lymphoma (NHL and HD)

RATIONALE: Donor peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy. Sometimes the transplanted cells are rejected by the body's normal tissues. Treatment with donor white blood cells may prevent this from happening.

PURPOSE: Phase II trial to study the effectiveness of donor peripheral stem cell transplantation followed by infusions of donor white blood cells in treating patients who have AIDS-related lymphoma.


  • Determine the response rate of patients with AIDS-related lymphoma treated with allogeneic peripheral blood stem cell (PBSC) transplantation followed by delayed donor leukocyte infusion.
  • Determine the complication rate of these patients treated with PBSC transplantation.
  • Determine the immune dysfunction and recovery of patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive cyclophosphamide IV over 60 minutes on days -5 to -3. Patients who have not received prior mediastinal radiotherapy receive thymic radiotherapy on day -1. Allogeneic peripheral blood stem cells are infused on day 0. Patients also receive anti-thymocyte globulin IV over 10-12 hours on days -1, 1, 3, and 5 and cyclosporine IV beginning on day -1, switching to oral when possible, and tapering until day 35.

In the absence of active acute graft-versus-host disease (GVHD), and at least 2 weeks after completion of cyclosporine, patients receive an infusion of donor leukocytes on or before day 49. Patients may receive a second donor leukocyte infusion if there is evidence of persistent malignancy and no GVHD.

Patients are followed through day 100, on days 120, 180, 270, and 365, and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 12-35 patients will be accrued for this study within 3-4 years.

Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Biological: anti-thymocyte globulin
  • Biological: therapeutic allogeneic lymphocytes
  • Drug: cyclophosphamide
  • Drug: cyclosporine
  • Procedure: peripheral blood stem cell transplantation
  • Radiation: radiation therapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2003
March 2003   (final data collection date for primary outcome measure)


  • Diagnosis of Hodgkin's disease or non-Hodgkin's lymphoma

    • Failed to achieve a complete remission with initial therapy OR
    • Relapsed after initial therapy
  • HIV-1 seropositive by Western Blot
  • Measurable or evaluable (e.g., pleural fluid involvement) disease
  • No leptomeningeal or parenchymal CNS involvement or active CNS leukemia
  • HLA-A, B, or DR antigen matched or 1 antigen mismatched related donor available
  • CD4 cell count greater than 100/mm3 (initial 12 patients) OR greater than 50/mm3 (subsequent patients)*
  • HIV RNA less than 110,000 copies/mL* NOTE: *Unless not receiving optimal anti-retroviral therapy as defined by current clinical standards



  • Physiologic 65 and under

Performance status:

  • Karnofsky 70-100%

Life expectancy:

  • Estimated disease-free survival less than 1 year


  • See Disease Characteristics


  • Bilirubin no greater than 2 mg/dL
  • Alkaline phosphatase no greater than 3 times upper limit of normal (ULN)*
  • SGOT or SGPT no greater than 3 times ULN*
  • Hepatitis B surface antigen negative NOTE: *Unless receiving indinavir


  • Creatinine no greater than 1.5 mg/dL
  • Creatinine clearance at least 50 mL/min


  • No symptomatic congestive heart failure
  • No angina pectoris
  • No uncontrolled hypertension
  • LVEF at least 45% by radionuclide ventriculography


  • No severe chronic obstructive lung disease
  • No symptomatic restrictive lung disease
  • DLCO greater than 50% predicted


  • No active uncontrolled infection
  • No history of cytomegalovirus retinitis or pneumonitis, even if treated
  • No other disease that would limit life expectancy
  • No symptomatic leukoencephalopathy
  • No neuropsychiatric abnormalities that would preclude transplantation
  • Human T-cell lymphotrophic virus (HTLV-1) antibody negative
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3 months after study


Biologic therapy:

  • Not specified


  • At least 1 week since prior chemotherapy

Endocrine therapy:

  • Not specified


  • Not specified


  • Not specified


  • No concurrent chronic suppressive therapy
up to 65 Years
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
CDR0000068894, AMC-028
Not Provided
AIDS Malignancy Consortium
AIDS Malignancy Consortium
National Cancer Institute (NCI)
Study Chair: David T. Scadden, MD Massachusetts General Hospital
AIDS Malignancy Consortium
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP